Pharmacology and pharmacokinetics of amiodarone

Amiodarone is a unique antiarrhythmic agent originally developed as a vasodilator. Classified electrophysiologically as a Type III antiarrhythmic, it also has both nonspecific antisympathetic and direct, fast channel-membrane effects. Hemodynamic effects of orally administered amiodarone (a negative inotropic agent) are usually negligible, and are usually compensated for by induced vasodilation. Effects on thyroid and hepatic function may help to explain some of the unique pharmacologic as well as toxicologic effects of the drug. Amiodarone is poorly bioavailable (20-80%) and undergoes extensive enterohepatic circulation before entry into a central compartment. The principal metabolite, mono-n-desethyl amiodarone is also an antiarrhythmic. From this central compartment, it undergoes extensive tissue distribution (exceptionally high tissue/plasma partition coefficients). The distribution half-life of amiodarone out of the central compartment to peripheral and deep tissue compartments (t1/2 alpha) may be as short as 4 hours. The terminal half-life (t1/2 beta) is both long and variable (9-77 days) secondary to the slow mobilization of the lipophilic medication out of (primarily) adipocytes. A pharmacokinetically based loading scheme is described, and data suggesting a role for routine amiodarone plasma levels are presented.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. Gardin, K. Kucher, B. Kiese, and S. Appel-Dingemanse Cannabinoid Receptor Agonist 13, a Novel Cannabinoid Agonist: First in Human Pharmacokinetics and Safety Drug Metab. Dispos., April 1, 2009; 37(4): 827 - 833. [Abstract] [Full Text] [PDF]

				F. Zannad, P. Bousquet, and L. Monassier CHAPTER 11 Clinical Pharmacology of Cardiovascular Drugs ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter. [Abstract] [Full Text] [PDF]

				P S Macdonald, A M Keogh, C Aboyoun, M Lund, R Amor, and D McCaffrey Impact of concurrent amiodarone treatment on the tolerability and efficacy of carvedilol in patients with chronic heart failure Heart, November 1, 1999; 82(5): 589 - 593. [Abstract] [Full Text]

				C. Torp-Pedersen, M. Moller, P. E. Bloch-Thomsen, L. Kober, E. Sandoe, K. Egstrup, E. Agner, J. Carlsen, J. Videbak, B. Marchant, et al. Dofetilide in Patients with Congestive Heart Failure and Left Ventricular Dysfunction N. Engl. J. Med., September 16, 1999; 341(12): 857 - 865. [Abstract] [Full Text] [PDF]

				B. M. Massie, S. G. Fisher, P. C. Deedwania, B. N. Singh, R. D. Fletcher, and S. N. Singh Effect of Amiodarone on Clinical Status and Left Ventricular Function in Patients With Congestive Heart Failure Circulation, June 15, 1996; 93(12): 2128 - 2134. [Abstract] [Full Text]